Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States


Autoři: Chun-Hsiang Hsu aff001;  John K. Chan aff002;  Chun-Hao Yin aff003;  Ching-Chih Lee aff003;  Chyi-Uei Chern aff005;  Cheng-I Liao aff005
Působiště autorů: Division of Chest Medicine, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan aff001;  Division of Gynecologic Oncology, California Pacific & Palo Alto Medical Foundation Sutter Health, San Francisco, CA, the United States of Amaerica aff002;  Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan aff003;  Department of Otolaryngology, Head and Neck Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan aff004;  Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan aff005;  National Yang-Ming University School of Medicine, Taipei, Taiwan aff006
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
doi: 10.1371/journal.pone.0227197

Souhrn

This study aimed to identify the trends in the incidence of thymic cancer, i.e., thymoma, thymic carcinoma, and thymic neuroendocrine tumor, in the United States. Data from the United States Cancer Statistics (USCS) database (2001–2015) and those from the Surveillance, Epidemiology, and End Results (SEER) database (SEER 9 [1973–2015], SEER 13 [1992–2015], and SEER 18 [2000–2015]) were used in this study. All incidences were per 100,000 population at risk. The trends in incidence were described as annual percent change (APC) using the Joinpoint regression program. Data from the USCS (2001–2015) database showed an increase in thymic cancer diagnosis with an APC of 4.89% from 2001 to 2006, which is mainly attributed to the significant increase in the incidence of thymoma and thymic carcinoma particularly in women. The incidence of thymic cancer did not increase from 2006 to 2015, which may be attributed to the increase in the diagnosis of thymic carcinoma from 2004 to 2015, with a concomitant decrease in thymoma from 2008 to 2015. Before declining, the age-specific incidence of thymic cancer peaked at ages 70–74 years, with a peak incidence at 1.06 per 100,000 population, and decreased in older age groups. The incidence of thymic cancer was higher in men than in women. Asian/Pacific Islanders had the highest incidence of thymoma, followed by black and then white people. The incidence of thymic carcinoma increased from 2004 to 2015, with a concomitant decrease in thymoma from 2008 to 2015. Asian/Pacific Islanders had the highest incidence of thymoma than other races.

Klíčová slova:

Age groups – Carcinomas – Disease surveillance – Epidemiological statistics – Histology – United States – Thymoma – Thymic tumors


Zdroje

1. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, fourth ed., International Agency for Research on Cancer (IARC), Lyon; 2015. p.184–186.

2. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol. 2010;5(10 Suppl 4):S260–5.

3. Ahmad U, Yao X, Detterbeck F, Huang J, Antonicelli A, Filosso PL, et al. Thymic carcinoma outcomes and prognosis: results of an international analysis. J Thorac Cardiovasc Surg. 2015;149:95–100. doi: 10.1016/j.jtcvs.2014.09.124 25524678

4. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart, International Agency for Research on Cancer (IARC), Lyon; 2004. p.190.

5. Gaur P, Leary C, Yao JC. Thymic neuroendocrine tumors: a SEER database analysis of 160 patients. Ann Surg. 2010;251:1117–21. doi: 10.1097/SLA.0b013e3181dd4ec4 20485130

6. Masaoka A. Staging system of thymoma. J Thorac Oncol. 2010;5(10 Suppl 4):S304–12.

7. Weksler B, Dhupar R, Parikh V, Nason KS, Pennathur A, Ferson PF. Thymic Carcinoma: A Multivariate Analysis of Factors Predictive of Survival in 290 Patients. Ann Thorac Surg. 2013;95:299–303. doi: 10.1016/j.athoracsur.2012.09.006 23141529

8. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg. 2003;76:878–84. doi: 10.1016/s0003-4975(03)00555-1 12963221

9. Gal AA, Kornstein MJ, Cohen C, Duarte IG, Miller JI, Mansour KA. Neuroendocrine tumors of the thymus: a clinicopathological and prognostic study. Ann Thorac Surg. 2001;72:1179–82. doi: 10.1016/s0003-4975(01)03032-6 11603433

10. Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 2003;105:546–51. doi: 10.1002/ijc.11099 12712448

11. de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ. Thymic epithelial tumors: A population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer. 2008;44:123–30. doi: 10.1016/j.ejca.2007.11.004 18068351

12. Siesling S, van der Zwan JM, Izarzugaza I, Jaal J, Treasure T, Foschi R, et al. Rare thoracic cancers, including peritoneum mesothelioma. Eur J Cancer. 2012;48:949–60. doi: 10.1016/j.ejca.2012.02.047 22406029

13. Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G. Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol. 2011;29:4820–7. doi: 10.1200/JCO.2011.36.0487 22105817

14. Health Promotion Administration, Ministry of Health and Welfare (Taiwan), Cancer Registry Annual Report, 2016. Available from: https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid = 269&pid = 10227

15. SEER*Stat Database: NPCR and SEER Incidence—U.S. Cancer Statistics Public Use Database, Nov 2017 submission (2001–2015). Created on 9/15/2018

16. Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database: Incidence—SEER 9 Regs Research Data, Nov 2017 Sub (1973–2015) <Katrina/Rita Population Adjustment>—Linked To County Attributes—Total U.S., 1969–2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission. Available from: https://www.seer.cancer.gov

17. Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database: Incidence—SEER 13 Regs Research Data, Nov 2017 Sub (1973–2015) <Katrina/Rita Population Adjustment>—Linked To County Attributes—Total U.S., 1969–2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission. Available from: https://www.seer.cancer.gov

18. Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database: Incidence—SEER 18 Regs Research Data, Nov 2017 Sub (1973–2015) <Katrina/Rita Population Adjustment>—Linked To County Attributes—Total U.S., 1969–2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission. Available from: https://www.seer.cancer.gov

19. Surveillance Research Program, National Cancer Institute SEER*Stat software, version 8.3.5. Available from: https://www.seer.cancer.gov

20. Kim HJ, Fay MP, Feuer EJ, Midthune DN. "Permutation tests for joinpoint regression with applications to cancer rates" Statistics in Medicine 2000; 19:335–351: (correction: 2001;20:655). doi: 10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z 10649300

21. Joinpoint Regression Program, Version 4.6.0.0—April 2018; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute.

22. Marchevsky A, Marx A, Strobel P, Suster S, Venuta F, Marino M, et al. Policies and reporting guidelines for small biopsy specimens of mediastinal masses. J Thorac Oncol. 2011;6(7 Suppl 3):S1724–9.

23. Detterbeck FC, Moran C, Huang J, Suster S, Walsh G, Kaiser L, et al. Which way is up? Policies and procedures for surgeons and pathologists regarding resection specimens of thymic malignancy. J Thorac Oncol. 2011;6(7 Suppl 3):S1730–8.

24. Marx A, Rieker R, Toker A, Langer F, Strobel P. Thymic carcinoma: is it a separate entity? From molecular to clinical evidence. Thorac Surg Clin. 2011;21:25–31. doi: 10.1016/j.thorsurg.2010.08.010 21070984

25. Weissferdt A, Moran CA. Immunohistochemistry in the Diagnosis of Thymic Epithelial Neoplasms. Appl Immunohistochem Mol Morphol. 2014;22:479–87. doi: 10.1097/PAI.0b013e3182a53856 24897066

26. Rosai J, Sobin LH. Histological Typing of Tumours of the Thymus. 2nd ed. Berlin, Germany: Springer-Verlag; 1999.

27. Oberg K, Hellman P, Ferolla P, Papotti M; ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii120–3.

28. Centers for Disease Control and Prevention, Available from: https://www.cdc.gov/cancer/npcr/about.htm.


Článek vyšel v časopise

PLOS One


2019 Číslo 12